Rolling Fields, Inc Medicare and Medicaid Location: 9108 State Highway 198, Conneautville, Pennsylvania 16406 Ratings: Phone: (814) 587-2012 |
News Archive
CEFALY Technology announced today that its received U.S. Food and Drug Administration approval of the Cefaly medical device for the preventative treatment for migraine headaches. Cefaly is the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain. It is expected to be available in the U.S. in early April.
More American workers and job applicants are testing positive for prescription opiates, according to U.S. general workforce data in the 2009 annual Drug Testing Index™ (DTI) released today by Quest Diagnostics Incorporated, the nation's leading provider of diagnostic testing, information and services. Results from more than 5.5 million urine drug tests reveal an 18 percent jump in opiate positives in the general U.S. workforce in a single year (2008 to 2009), and a more than 40 percent climb from 2005 to 2009.
Could parental exposure to solvents at work be linked to autism spectrum disorder (ASD) in their children? According to an exploratory study by Erin McCanlies, a research epidemiologist from the National Institute for Occupational Safety and Health (NIOSH), and colleagues, such exposures could play a role, but more research would be needed to confirm an association.
Researchers have uncovered a new way in which a cell protein protects cancer cells from a wide range of chemotherapeutic drugs, identifying a possible target for improving treatment outcomes for patients.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
› Verified 5 days ago